Inactive Instrument

Ambrx Biopharma Inc. Stock price Nasdaq

Equities

AMAM

US02290A1025

Biotechnology & Medical Research

Delayed Nasdaq 04:00:00 2024-03-06 pm EST 5-day change 1st Jan Change
28 USD +0.07% Intraday chart for Ambrx Biopharma Inc. +0.21% +119.95%
Dynamic Chart

Latest transcript on Ambrx Biopharma Inc.

Ambrx Biopharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its ADC targeting Human epidermal growth factor receptor 2 (HER2). It uses genetic code technology platform to discover and develop engineered precision biologics. Its genetic code technology platform allows to incorporate, in a site-specific manner, synthetic amino acids (SAA), into proteins within living cells. Its SAA incorporation technology is designed to develop a range of product candidate modality, such as modified cytokines and bispecific antibodies, and others.
More about the company
  1. Stock
  2. Equities
  3. Stock Ambrx Biopharma Inc.
  4. Stock Ambrx Biopharma Inc. - Nasdaq